leisure time -WSS

leisure time

author：Wikipedia 2025-10-02 07:05:49 - browse：584

At some point this summer, the drugmaker Novo Nordisk will release results from a closely watched study that, if successful, could further uncork demand for new obesity medications, streamline insurance coverage for the therapies, and demonstrate long-lasting health benefits.

The Select trial, as the study is called, is the first large, randomized trial to test whether long-term treatment with a weight loss drug can meaningfully improve patients’ cardiovascular health. Novo is testing Wegovy, a weekly injection also sold under the brand name Ozempic for type 2 diabetes, against placebo in the five-year study.

The implications are massive, and not just for Novo. Wegovy is part of a class of medicines that target a hormone called GLP-1, which curbs patients’ appetites. Those drugs have demonstrated an ability to help people lose dramatic amounts of weight in clinical trials, but payers, including Medicare, have been slow to reimburse for them without definitive data on their long-term health benefits.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： It's time to retire 'poor historian' from clinicians' vocabularies

knowledge

WSS

Case highlights the risks of experimental stem cell therapy

HIV vaccine remains elusive. Immunologists keep trying new ideas

Wearables generate powerful data but its not useful to doctors, yet

Glen Campbell's doctor discusses his public struggle with Alzheimer's

Nonprofit, backed by Microsoft, to certify AI tools in health care

Mayo Clinic partners with supercomputer AI firm Cerebras at JPM

focus

leisure time

entertainment

DIEP, the 'gold standard' of breast reconstruction, is under threat

How a billionaire couple greased the skids for Pelosi’s drug pricing bill

Trump demands the U.S. pay no more for drugs than other countries … again

Arena BioWorks launches in Cambridge to speed drug discovery

Duchenne breakthrough therapy leaves behind pioneering families

Second House panel advances two

Psychedelics group wrestles with new pharma identity

Fauci's latest grilling in Congress: 9 hours, behind closed doors

Dobbs anniversary: the lost opportunity of abortion as health care

NVIDIA and Google execs on the future of AI and drug discovery

hotspot

HIV vaccine remains elusive. Immunologists keep trying new ideas

When prostate cancer spreads, where it goes matters

It's time to retire 'poor historian' from clinicians' vocabularies

Rune Labs, whose app tracks Parkinson's symptoms, raises $12M

NVIDIA and Google execs on the future of AI and drug discovery

Can we make enough H5N1 bird flu vaccine if there's a pandemic?

knowledge

Wikipedia

knowledge

knowledge